GSE135383
C. difficile-associated antibiotics prime the host for infection by a microbiome-independent mechanism
The most clinically relevant risk factor for Clostridioides difficile-associated disease (CDAD) is recent antibiotic treatment. Though most broad-spectrum antibiotics significantly disrupt the structure of the gut microbiota, only particular ones increase CDAD risk, suggesting additional factors might increase the risk from certain antibiotics. Here we show that commensal-independent effects of antibiotics collectively prime an in vitro germ-free human gut for CDAD. We found a marked loss of mucosal barrier and immune function with CDAD-associated antibiotic pretreatment distinct from pretreatment with an antibiotic unassociated with CDAD, which did not reduce innate immune or mucosal barrier functions. Importantly, pretreatment with CDAD-associated antibiotics sensitized mucosal barriers to C. difficile toxin activity in primary cell-derived enteroid monolayers. These data implicate commensal-independent host changes in the increased risk of CDAD with specific antibiotics. Our findings are contrary to the previously held belief that antibiotics allow for CDAD solely through disruption of the microbiome. We anticipate this work to suggest potential avenues of research for host-directed treatment and preventive therapies for CDAD, and to impact human tissue culturing protocols. Overall design: Antibiotics used: Clindamycin, ciprofloxacin, tigecycline. Clindamycin and ciprofloxacin compared to untreated, while tigecycline compared to DMSO. 6 replicates per condition. Hi: Clindamycin 300ug/ml, Ciprofloxacin 200ug/ml, tigecycline 20ug/ml. Low: Clindamycin 3ug/ml, ciprofloxacin 5ug/ml, tigecycline 1ug/ml